SUTRO BIOPHARMA, INC. Cash Flow Statement
STRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$192M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
SUTRO BIOPHARMA, INC. used $192M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$227.5M | -$119.2M | -$105.5M | -$119.2M | -$55.7M | -$35.3M | -$19.7M | $1.7M |
| Depreciation & Amortization | $7.2M | $5.7M | $4.8M | $4.3M | $4.8M | $4.5M | $5.0M | $5.7M |
| Operating Cash Flow | -$191.5M | $3.5M | -$81.7M | -$67.8M | -$65.0M | $12.7M | -$37.1M | -$13.2M |
| Capital Expenditures | - | - | - | - | - | - | - | $4.4M |
| Free Cash Flow | - | - | - | - | - | - | - | -$17.5M |
| Share Buybacks | - | - | $7.0K | $7.0K | $7.0K | - | - | - |
| FCF Margin | - | - | - | - | - | - | - | -29.4% |